Member Info for daveboy19

Take your point on board. But also, why would the CEO want to release results early without much positive info? Surely he will have an idea of the sales in US, and if they are good, let investors know they are happy with progress. Also, some news on Norgine expansion and sales would further strengthen the report. His options are also underwater, so more incentive, but all just mho. Good luck to everyone invested. It's been a long road.

For a positive update tomorrow alongside H1 results. I also hope there might be some figures coming out of the US rather than just optimistic statements. Early days there, but off to a flyer would be most welcome. GLALTH.

Probably, and also interesting - many thanks.

They can get through whatever they want to, whenever they want to. The size of Synairgen's P2 trial was called too small, but it was considerably larger than the vaccine trials! We're playing live guinea pigs, but that's okay because they say it is okay. I was bad for 10 days after the 2nd jab, never been one for getting ill much, go to the gym 3-4 times a week, and try to generally look after myself. I have since had numerous ill days with ranging symptoms. Maybe a coincidence, maybe not. Point being, we don't know, but we may be finding out at some point in the future. Yes, it was needed for the pandemic, but blocking SNG001 is just an insanity I can not comprehend, unless you look at Migsmcl86 line :-
'Personally I think SNG has been suppressed as a useful drug for Covid to ensure Vaccine uptake was high and line the pockets of pharma'.
I have to agree with you on that point. It's like two ends of a spectrum.

Just shows again that pi myth that ii are 'in the know' and they wouldn't have invested otherwise. They are comprised of human beings, who make mistakes. The wording of the last 2 RNS, would have had me cancelling my w/e rounds of golf with John Shaw, were I one of those said ii managers - and that's a sure thing !

Agreed, and sadly there are at least 2 cancer drugs that I know of that are definitely being held back. Chemo drug companies have too much skin in the game. This situation here feel like a parallel universe after last July's P2 results. Scandalous that emergency use could not be given, it has reams of safety attached but still has to jump through hoops.

You'd think they might beat around the bush a bit, instead of coming straight in with badly worded and punctuated criticisms !
Maybe an embittered Revolymer investor. There is a bunch of hyenas appeared on the ADVFN board performing in a similar fashion. One has quoted from this board, so I wouldn't be surprised if LG isn't another one of her many aliases.

But how could that many scientists, doctors and medical personnel get it that wrong.... binary is therefore obsolete in this situation. By about a year or so.

Good call by the looks of it, Ray.

Best wishes to you as well, SYN00GOLD - at some point good will prevail.

Have a look at my chats on advfn with patt week or so back. When Greg reported for his last company, it was fairly rapid and then regularly with investors. Hopefully, he will be as prompt here, maybe commencing mid-August my guess only.

''My suspicious mind says they never confirmed it did launch, just that it was on schedule at the last update. I'd love an update.''
Curious comment - not sure if you've seen this or not, but here it is anyway for your suspicious mind!

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")



US launch of Accrufer® confirmed for July 1, 2021



London, UK, June 24, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), confirms that, in line with prior guidance, it will launch Accrufer® in the US on July 1, 2021.



Launch stocks of Accrufer® are currently being distributed through the wholesaler channels and will be available to doctors and other prescribers in all parts of the US by July 1, 2021. A sales force including 30 sales representatives has been recruited and trained and will be starting to contact key prescribers during next week.



Greg Madison, CEO of Shield, said "We are pleased to make Accrufer® available to physicians and their patients in the US. Iron deficiency and iron deficiency anemia are significant challenges for millions of patients. Accrufer® represents a novel form of oral iron which offers clinical effectiveness while being well tolerated in clinical trials, and has the potential to be a significant advance for those patients in the US."

Fully stated and backed up !
Can't imagine they would update until mid August at the earliest, but that comment was down ticked on ADVFN so wtfdik lol.

Correct - 31.19%.

Yes, hard to find such info among all the Boris bashing, vaccine opinions and other non company related 'debate'.

Not much Synairgen/SNG001 chat going on then, as per.

From today's press:-

Mr Walker said Iceland has a 'double pronged problem' of staff shortages and a lack of lorry drivers to bring in food, forcing them to draft in 2,000 temporary workers to keep Iceland running.

They will make a nice packet from this. All the big 5 will need people as well.

Nice to see it hasn't boosted the ever drifting price at all !!

US launch of Accrufer®
There are estimated to be 10 million oral and 2.3 million IV iron
prescriptions annually in the US and peak sales potential of
Accrufer® in the US could be as much as $300m-$400m per annum.
Since launching on July 1, stocks of Accrufer® have been distributed
through wholesaler channels and are available to doctors and other
prescribers in all parts of the US.
The Wholesaler Acquisition Cost (headline price of a pharmaceutical
product in the US) for Accrufer® has been set at $500 per pack (which
contains 30 days’ supply at two capsules per day).

Just out from Walbrook:-
US launch of Accrufer®
There are estimated to be 10 million oral and 2.3 million IV iron
prescriptions annually in the US and peak sales potential of
Accrufer® in the US could be as much as $300m-$400m per annum.
Since launching on July 1, stocks of Accrufer® have been distributed
through wholesaler channels and are available to doctors and other
prescribers in all parts of the US.
The Wholesaler Acquisition Cost (headline price of a pharmaceutical
product in the US) for Accrufer® has been set at $500 per pack (which
contains 30 days’ supply at two capsules per day).

GSK had one, but it is miles behind this, but wtfdik.